Research across Tuberculosis
Related studies from across the Tuberculosis family.
5 trials tracked for Latent Tuberculosis Infection: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 175 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
In a Phase 3 trial of isoniazid and rifapentine for latent tuberculosis infection, the treatment was evaluated in terms of completion rates and safety. The study observed varying counts of participants completing treatment across different groups (294, 271, 266, 294, 248, and 249).
Safety data for the isoniazid and rifapentine regimen showed a total of 23, 23, and 29 instances of drug-related Grade 3 or 4 adverse events or death across the study groups. Reasons for failure to complete treatment were also documented with counts of 3, 7, 4, 12, 18, and 14 respectively.
AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Tuberculosis family.